Oramed Pharmaceuticals Valuation
| ORMP Stock | USD 2.33 0.04 1.69% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Oramed Pharmaceuticals holds a recent Real Value of $1.95 per share. The prevailing price of the company is $2.33. Our model determines the value of Oramed Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of 0.0289, shares outstanding of 40.77 M, and Shares Owned By Institutions of 17.32 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oramed Pharmaceuticals' valuation include:
Price Book 0.6004 | Enterprise Value | Enterprise Value Ebitda 0.5244 | Price Sales 141.5422 | Trailing PE 4.549 |
Overvalued
Today
Please note that Oramed Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Oramed Pharmaceuticals is based on 3 months time horizon. Increasing Oramed Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Oramed Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 2.33, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.33 | Real 1.95 | Target 3.25 | Hype 2.33 | Naive 2.33 |
The intrinsic value of Oramed Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oramed Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Oramed Pharmaceuticals helps investors to forecast how Oramed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oramed Pharmaceuticals more accurately as focusing exclusively on Oramed Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oramed Pharmaceuticals' intrinsic value based on its ongoing forecasts of Oramed Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oramed Pharmaceuticals' closest peers.
Oramed Pharmaceuticals Cash |
|
Oramed Valuation Trend
Oramed Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Oramed Pharmaceuticals' financial worth over time. Using both Oramed Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Oramed Pharmaceuticals Total Value Analysis
Oramed Pharmaceuticals is now expected to have valuation of (47.94 M) with market capitalization of 94.58 M, debt of 51.62 M, and cash on hands of 133.91 M. The negative valuation of Oramed Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Oramed Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(47.94 M) | 94.58 M | 51.62 M | 133.91 M |
Oramed Pharmaceuticals Investor Information
About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oramed Pharmaceuticals had not issued any dividends in recent years. The entity had 1:12 split on the 23rd of January 2013. Based on the key indicators related to Oramed Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Oramed Pharmaceuticals is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in April.Oramed Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Oramed Pharmaceuticals has an asset utilization ratio of 0.61 percent. This connotes that the Company is making $0.006076 for each dollar of assets. An increasing asset utilization means that Oramed Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Oramed Pharmaceuticals Ownership Allocation
Oramed Pharmaceuticals owns a total of 40.77 Million outstanding shares. Oramed Pharmaceuticals holds 10.62 pct. of its outstanding shares held by insiders and 17.32 pct. owned by third-party entities. On February 26, 2025, Representative Brad Knott of US Congress acquired $15k to $50k worth of Oramed Pharmaceuticals's common stock.Oramed Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 1.34 M. Net Income was 5.09 M with profit before overhead, payroll, taxes, and interest of 2.7 M.About Oramed Pharmaceuticals Valuation
The stock valuation mechanism determines Oramed Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Oramed Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Oramed Pharmaceuticals. We calculate exposure to Oramed Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oramed Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.5 M | 1.9 M | |
| Pretax Profit Margin | 3.42 | 3.59 | |
| Operating Profit Margin | (13.53) | (14.21) | |
| Net Profit Margin | 3.71 | 3.90 | |
| Gross Profit Margin | 0.87 | 0.65 |
Oramed Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Oramed Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40.6 M |
Oramed Pharmaceuticals Current Valuation Indicators
Oramed Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Oramed Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oramed Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oramed Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oramed Pharmaceuticals' worth.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.